Aptose Biosciences Inc.

Posters & Presentations

All Poster Presentation
December 11, 2022 Poster

2022 ASH Poster - A Phase 1 a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes

2022 ASH Poster - A Phase 1 a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: View Poster
June 10, 2022 Poster

2022 EHA Poster - Myeloid Kinome Inhibitor HM43239 Overcomes Acquired Resistance in Acute Myeloid Leukemia Models

2022 EHA Poster - Myeloid Kinome Inhibitor HM43239 Overcomes Acquired Resistance in Acute Myeloid Leukemia Models: View Poster
December 13, 2021 Poster

2021 ASH Poster - A Phase 1a/b Study of APTO-253 in R/R AML and HR-MDS

2021 ASH Poster - A Phase 1a/b Study of APTO-253 in R/R AML and HR-MDS: View Poster
December 11, 2021 Poster

2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R AML

2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R AML: View Poster
December 11, 2021 Poster

2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R B-Cell Malignancies

2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R B-Cell Malignancies: View Poster
June 11, 2021 Poster

2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in R/R B-Cell Malignancies

2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in R/R B-Cell Malignancies: View Poster
June 11, 2021 Poster

2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in R/R AML or HR MDS

2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in R/R AML or HR MDS: View Poster
December 6, 2020 Poster

2020 ASH Poster - A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with R/R CLL/SLL or NHL

2020 ASH Poster - A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with R/R CLL/SLL or NHL : View Poster
December 5, 2020 Poster

2020 ASH Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in Patients with R/R AML or HR-MDS

2020 ASH Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in Patients with R/R AML or HR-MDS: View Poster